JP2021535126A5 - - Google Patents

Info

Publication number
JP2021535126A5
JP2021535126A5 JP2021510174A JP2021510174A JP2021535126A5 JP 2021535126 A5 JP2021535126 A5 JP 2021535126A5 JP 2021510174 A JP2021510174 A JP 2021510174A JP 2021510174 A JP2021510174 A JP 2021510174A JP 2021535126 A5 JP2021535126 A5 JP 2021535126A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitors
composition according
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021510174A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535126A (ja
JP7161605B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/057259 external-priority patent/WO2020044266A1/en
Publication of JP2021535126A publication Critical patent/JP2021535126A/ja
Publication of JP2021535126A5 publication Critical patent/JP2021535126A5/ja
Application granted granted Critical
Publication of JP7161605B2 publication Critical patent/JP7161605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510174A 2018-08-31 2019-08-28 Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ Active JP7161605B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862726172P 2018-08-31 2018-08-31
US62/726,172 2018-08-31
US201962883860P 2019-08-07 2019-08-07
US62/883,860 2019-08-07
PCT/IB2019/057259 WO2020044266A1 (en) 2018-08-31 2019-08-28 Combinations for treatment of nash/nafld and related diseases

Publications (3)

Publication Number Publication Date
JP2021535126A JP2021535126A (ja) 2021-12-16
JP2021535126A5 true JP2021535126A5 (enExample) 2022-02-22
JP7161605B2 JP7161605B2 (ja) 2022-10-26

Family

ID=68165623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510174A Active JP7161605B2 (ja) 2018-08-31 2019-08-28 Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ

Country Status (23)

Country Link
US (2) US11254660B2 (enExample)
EP (1) EP3843740A1 (enExample)
JP (1) JP7161605B2 (enExample)
KR (1) KR102614808B1 (enExample)
CN (1) CN112955147A (enExample)
AU (1) AU2019329884B2 (enExample)
BR (1) BR112021003039A2 (enExample)
CA (1) CA3110601C (enExample)
CL (1) CL2021000491A1 (enExample)
CO (1) CO2021002230A2 (enExample)
CR (1) CR20210110A (enExample)
DO (1) DOP2021000036A (enExample)
EC (1) ECSP21012501A (enExample)
IL (1) IL281093B2 (enExample)
MA (1) MA53496A (enExample)
MX (1) MX2021002428A (enExample)
PH (1) PH12021550339A1 (enExample)
PY (1) PY1972032A (enExample)
SG (1) SG11202101503RA (enExample)
TW (1) TWI718644B (enExample)
UY (1) UY38351A (enExample)
WO (1) WO2020044266A1 (enExample)
ZA (1) ZA202101090B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
EA202191432A1 (ru) 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
WO2020142365A1 (en) * 2018-12-31 2020-07-09 Christos Mantzoros Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
AU2020256647B2 (en) 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
JP2022058085A (ja) * 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) * 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
IL296100A (en) * 2020-03-11 2022-11-01 Dong A St Co Ltd A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis
WO2021211959A2 (en) * 2020-04-18 2021-10-21 Inipharm, Inc. Methods and compositions for treating drug induced steatohepatitis
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN117645601A (zh) * 2020-06-10 2024-03-05 重庆康丁医药技术有限公司 一种具有心血管益处的glp-1小分子
CN113816948B (zh) * 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
JP2023538408A (ja) * 2020-08-21 2023-09-07 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｇｌｐ－１ｒ作動薬としての化合物
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112635049A (zh) * 2020-12-23 2021-04-09 无锡市第二人民医院 一种研究HSD17B13 rs72613567基因变异和肾功能损伤之间关系的方法
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4490155A1 (en) 2022-03-09 2025-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN121002014A (zh) 2022-12-15 2025-11-21 加舒布鲁姆生物公司 具有glp-1激动剂活性的化合物的盐和固体形式
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
EP4731212A1 (en) * 2023-06-20 2026-04-29 Sagimet Biosciences Inc. Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
WO2025080818A1 (en) * 2023-10-10 2025-04-17 Sagimet Biosciences Inc. Combinations of fasn inhibitors and glp-1 agonists for liver diseases
CN118787746B (zh) * 2024-07-01 2025-09-16 安徽省立医院(中国科学技术大学附属第一医院) 脂肪酸合成酶抑制剂在预防及治疗药物性肝损伤中的应用
CN120698959B (zh) * 2025-05-29 2026-01-23 河北医科大学 一种达格列净-依折麦布共无定形物及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CA2439152C (en) 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2003072197A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Acc inhibitors
EA011086B9 (ru) 2004-05-12 2012-08-30 Пфайзер Продактс Инк. Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
WO2008065508A1 (en) 2006-11-29 2008-06-05 Pfizer Products Inc. Spiroketone acetyl-coa carboxylase inhibitors
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
EP2297164A1 (en) 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
ES2380408T3 (es) 2008-08-28 2012-05-11 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
WO2010103437A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
CA2754523A1 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
GEP20135907B (en) 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
CH702192A1 (de) 2009-11-04 2011-05-13 New Dent Ag Keramisches Implantat.
DK2621493T3 (en) * 2010-09-30 2016-10-24 Pfizer N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MX2017008844A (es) 2015-01-09 2018-03-14 Gilead Apollo Llc Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
TN2018000198A1 (en) 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN106271089B (zh) 2016-09-30 2019-01-25 英诺激光科技股份有限公司 一种激光薄膜刻蚀装置及方法
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
EP3713942B8 (en) 2017-11-21 2023-04-12 Pfizer Inc. Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid

Similar Documents

Publication Publication Date Title
JP2022540000A5 (enExample)
JP2020200308A5 (enExample)
US10017468B2 (en) Substituted pyrrolidines as G-protein coupled receptor 43 agonists
US20080058339A1 (en) New compounds
JP6435323B2 (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
US8962609B2 (en) Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them
JP5301456B2 (ja) ヘテロアリールオキシキナゾリン誘導体
TW202115086A (zh) Bckdk抑制劑
HRP20201748T1 (hr) Inhibitori diacilglicerol-aciltransferaze
JP6491656B2 (ja) 新規アザベンズイミダゾール誘導体
US10603317B2 (en) Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US20240294525A1 (en) Compounds as glp-1 receptor agonists and uses thereof
JP2019524831A5 (enExample)
US10894787B2 (en) Modulators of the GPR119 receptor and the treatment of disorders related thereto
US10196381B2 (en) Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition containing the same, preparation method and use thereof
EA025859B1 (ru) Конденсированное бициклическое 2,4-диаминопиримидиновое производное в качестве двойного alk и fak ингибитора
US20170217918A1 (en) Antidiabetic bicyclic compounds
JP2014518287A (ja) 置換キナゾリン、これらの調製及び医薬組成物中のこれらの使用
EA020009B1 (ru) Комбинированная терапия при лечении диабета
US20120289497A1 (en) Fused pyridine derivatives
US12264139B2 (en) Aryl sulfonamides as BLT1 antagonists
WO2016101927A1 (zh) 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物
US20250235510A1 (en) Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist peptides
RU2013146619A (ru) Производные пиридопиразина и их применение
TW201609644A (zh) 吲哚酮衍生物、其製備及其治療用途